Focus | Pipeline

We are presently using the STAR-D platform to develop treatments for rare, orphan skin diseases caused by the absence of, or a mutation in, a single gene. In addition to this work, we are currently leveraging our platform to expand our pipeline to include additional dermatological indications.


Product Indication Discovery Preclinical Phase I/II Phase III Marketed
KB103¤ Dystrophic EB Read More
KB104 Netherton Syndrome Read More
KB105¤ TGM1-deficient ARCI Read More
KB107 Junctional EB Read More
KB301/KB302 Aesthetic Skin Conditions Read More

Two Undisclosed Targets

KB5xx Chronic Skin Diseases Read More

Two Undisclosed Targets

†: FDA Orphan Drug Designation;
‡: EMA Orphan Drug Designation;
•: Fast-track Designation;
¤: FDA Rare Pediatric Disease Designation.
12 months